Stock AnalizPacira BioSciences, Inc. PCRX
Biotechnology: Pharmaceutical Preparations · IPO 2011 · data as of November 13, 2026
Pacira BioSciences, Inc. (PCRX) is a healthcare company listed in the US with a market value of about $1.5B. In the twelve months to September 30, 2026 it had revenue of $743M and net income of $38M, a net margin of 5.1%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (1/5).
Key numbers: a P/E of 39.2, a price to free cash flow of 8.7, 5-year revenue growth of 11% a year, a 5-year average ROIC of 2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 30% below the current price.
Score: 2.0 / 5
Checks passed
- P/FCF below 20
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Positive free cash flow
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $743M | $726M | $701M | $675M | $667M | $542M | $430M | $421M | $337M | $287M | $276M |
| Net income | $38M | $7M | -$100M | $42M | $16M | $42M | $146M | -$11M | -$471000 | -$43M | -$38M |
| Free cash flow | $169M | $137M | $179M | $139M | $115M | $80M | $39M | $60M | $34M | -$1M | $9M |
| EPS (diluted) | $0.93 | $0.16 | $-2.15 | $0.89 | $0.34 | $0.92 | $3.33 | $-0.27 | $-0.01 | $-1.07 | $-1.02 |
| Net margin | 5.1% | 1.0% | -14.2% | 6.2% | 2.4% | 7.8% | 33.9% | -2.6% | -0.1% | -14.9% | -13.7% |
| ROIC | — | 1.4% | -4.1% | 4.1% | 3.1% | 5.8% | 3.6% | 1.2% | 2.1% | -3.5% | -5.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 7 analysts is $33.57, 8% below the current price; targets range from $25.00 to $36.50; the consensus rating is “Hold”; expected EPS is $3.04 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Pacira BioSciences’s P/E ratio?
About 39.2, based on the last twelve months of diluted earnings per share (forward P/E about 10.7).
Is Pacira BioSciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 30% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Pacira BioSciences pay a dividend?
Not currently.
Is Pacira BioSciences a good stock to buy?
We do not give buy or sell advice. Pacira BioSciences scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.